PLANS to start testing a
stem-cell treatment for strokes were welcomed last month, as patients
become more anxious for therapies to emerge from this often
controversial area of science. Some
campaigners believe the advance is not such good news, and will lead to
a risky treatment being tested on Scottish patients. Scientists, on the
other hand, have defended the trial, which will involve injecting cells
made from a human foetus ino patient's brains.
The firm that developed the cells, Reneuron, applied to begin trials in
the United States two years ago, but the treatment has not yet been
approved by the US Food and Drug Administration. This has raised
concern among some ethical campaigners, who question whether watchdogs
in the UK are right in letting the trial proceed. One told me: "I think
one should be extremely cautious if anyone in Glasgow is approached to
take part in this trial. They should run a mile."
But scientists
believe such trials are long overdue. Most of the research conducted so
far using stem cells has remained at a very basic stage, frustrating
patients who want treatments to be made available faster rather than
remain in the lab.
The UK Stem Cell Network, among others, has
welcomed the progress being made. An insider said "due process" was
being followed in the UK in terms of the trial being approved by the
Medicines and Healthcare products Regulatory Agency.
He said there were only a "handful" of stage one clinical trials involving stem cells currently under way.
"There are so few of these trials going on at the moment that new ones, properly approved, are to be welcomed," he said.
But
he admitted no phase-one clinical trial involving stem cells or any
other agent could be guaranteed to be 100 per cent safe. "Patients who
volunteer to participate are told about the risks and they participate
voluntarily," he said. "There's nothing different here simply because
it is stem cells."